Insilico Medicine (3696) said its self-developed AI-driven potential best-in-class novel pan-TEAD inhibitor ISM6331 has been granted Fast Track designation by the U.S. Food and Drug Administration for use in adults with unresectable malignant pleural mesothelioma whose disease progressed after prior anti-PD-1 antibody treatment, with or without anti-CTLA-4 antibody treatment, and platinum-based chemotherapy, according to Ming Pao.